FDA blocked from approving abortion pills; existing drug faces strict new limits

What it does

This bill prohibits the FDA from approving new abortion medications and blocks investigational exemptions for them. For mifepristone (the one abortion drug already approved), it imposes strict new requirements: limiting dispensing to in-person administration in medical offices only (not pharmacies), requiring prescribers to have surgical abortion capabilities and ability to diagnose ectopic pregnancies, restricting use after 70 days gestation, and mandating detailed adverse-event reporting to the FDA and state authorities. Existing investigational studies of abortion drugs have 3 years to wind down before their exemptions are rescinded.

Why we flagged it

The bill's core mechanism is to prohibit FDA approval of new abortion drugs and impose restrictive regulatory requirements on the one already-approved medication (mifepristone). It is functionally a de facto ban on medication abortion through regulatory constraint, not an outright prohibition.

What the text implies

• The 70-day gestation limit is more restrictive than current FDA labeling (which permits use through 77 days) and may conflict with state laws permitting abortion beyond that threshold, creating legal uncertainty.
• Requiring prescribers to have surgical abortion capabilities and ability to manage severe complications may eliminate medication abortion access in settings (telehealth, rural clinics) where surgical backup is unavailable, effectively creating geographic access disparities.
• The adverse-event reporting requirement, while framed as safety, creates a detailed registry of medication abortion use that could be subpoenaed by state prosecutors in jurisdictions criminalizing abortion, chilling provider participation.
• The 3-year wind-down for existing investigational exemptions may prematurely terminate ongoing clinical research into safety and efficacy, removing data that could inform future regulatory decisions.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill restricts access to a medication already approved by the FDA and used by hundreds of thousands of Americans annually. It imposes prescriber requirements that will reduce the number of providers willing or able to offer medication abortion, effectively narrowing access particularly in rural and underserved areas. The reporting and certification burdens may also increase costs and delay care.

Named in the bill

FDA, mifepristone, Federal Food, Drug, and Cosmetic Act, Section 505, Section 503(f), Section 505-1 (REMS)

Where it stands

80 cosponsors: 80 Republicans.

• Jan 23, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jan 23, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $420,000 in lobbying spend. A filing names 51 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Robert Latta, the sponsor, reported $876,626 in PAC receipts in the 2026 cycle.

• Susan B Anthony List — $420,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.